



nContact Receives Mind To Market Award from Eastern North Carolina Chapter of National Multiple Sclerosis Society

On September 8, 2009, The Eastern North Carolina Chapter of the National Multiple Sclerosis Society announced nContact as the annual winner of The Mind to Market Award. The nContact team has successfully demonstrated the potential to greatly impact healthcare with its *Numeris[®] Guided Coagulation Device with VisiTrax[®]*. The award is open to the general health and life sciences community and is not specific to multiple sclerosis or neurological projects. The award was presented to nContact during the Society's fundraising event, *The Dinner of Champions*.

The following is an excerpt from the National Multiple Sclerosis Society's press release announcing the award winner:

"The Mind to Market Award was presented to nContact Surgical for successfully taking a concept through research and development and enabling a marketable procedure that has the potential to make a great impact. nContact has developed a novel technology for creating lesions on a beating heart through a minimally invasive approach without chest incisions or ports. This technology offers a closed chest option for the treatment of arrhythmias, including atrial fibrillation. Company president John Funkhouser and technology developers Jim Whyne and Sidney Fleischman accepted the award. "It is a great honor to have not only our technology recognized, but the commitment being made to healthcare by our outstanding team of employees at nContact and the physicians who make this possible," says Funkhouser."

About nContact Surgical, Inc.

nContact is a medical device company founded in 2005 with the company mission to develop devices for the endoscopic treatment of arrhythmias, including atrial fibrillation (AF). The Numeris[®] Coagulation System with VisiTrax[®] is based on the unique integration of suction, perfusion, and RF energy to ensure the creation of visible, non-conductive, bi-atrial epicardial lesions on a beating heart.

To date, The Numeris Coagulation System with VisiTrax is indicated for the coagulation of cardiac tissue in the United States. nContact has initiated clinical studies for the treatment of AF in both open and closed chest procedures. The Numeris Coagulation System with VisiTrax has CE Mark approval in Europe for the specific indication for the coagulation of cardiac tissue for the treatment of atrial fibrillation and atrial flutter.

#

nContact, Inc.

1001 Aviation Parkway, Ste 400
Morrisville, NC 27560
T (919) 466-9810
F (919) 466-9811

Media Contacts

Angela Moser
nContact Surgical, Inc.
amoser@ncontactsurgical.com

Scott Lerman
The Ruth Group
T (646) 536-7013
slerman@theruthgroup.com